SOUTH SAN FRANCISCO, Calif.,
April 5, 2024 /PRNewswire/ -- IDEAYA
Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology
company committed to the discovery and development of targeted
therapeutics, today announced that, on March
28, 2024, the Compensation Committee of IDEAYA's Board of
Directors granted non-qualified stock options to purchase an
aggregate of 70,000 shares of the Company's common stock to two
newly hired employees. The stock options were granted under the
IDEAYA Biosciences, Inc. 2023 Employment Inducement Incentive Award
Plan (2023 Inducement Plan) as an inducement material to such
individuals' entering into employment with IDEAYA in accordance
with Nasdaq Listing Rule 5635(c)(4).
The 2023 Inducement Plan is used exclusively for the grant of
equity awards to individuals who were not previously employees of
IDEAYA, or following a bona fide period of non-employment, as an
inducement material to such individuals' entering into employment
with IDEAYA, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of $43.88 per share, which is equal to the closing
price of IDEAYA's common stock on The Nasdaq Global Select
Market on the date of grant. The stock options have a 10-year term
and will vest over four years, with 25% of the options vesting on
the first anniversary of the vesting commencement date and the
remaining 75% of the options vesting in equal monthly installments
over the three years thereafter. Vesting of the stock options is
subject to such employee's continued service to IDEAYA on each
vesting date.
About IDEAYA Biosciences
IDEAYA is a precision
medicine oncology company committed to the discovery and
development of targeted therapeutics for patient populations
selected using molecular diagnostics. IDEAYA's approach integrates
capabilities in identifying and validating translational biomarkers
with drug discovery to select patient populations most likely to
benefit from its targeted therapies. IDEAYA is applying its early
research and drug discovery capabilities to synthetic lethality –
which represents an emerging class of precision medicine
targets.
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
investor@ideayabio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-302107526.html
SOURCE IDEAYA Biosciences, Inc.
